RE:RE:RE:RE:RE:RE:RE:RE:Presentation
Redbaron2211 wrote: Salley maybe I'm unrealistic it's a possibility but we had the same divergence last year before the AGM and many of the optimistic view points did manifest. If investors are dissatisfied with management's performance they should vote but call the company and think for yourself.
I personally dont feel/think Philip is an ego freak, I hope he will get some satisfaction in proving the naysayers wrong and if it acts as a motivation that's fine. Anyways I don't get the same impressions, possibly I'm blind to it who knows.
Red,
The difference was in December we did not know what the initial results of the clinical trials were. For once management had some leverage , the share price was close to $3. So what does Toleikis do ? He did a deal at $1.20 with a full warrant at 1.70 and 15% over allotment plus 2% legal fees . All in all 50 million shares for a bought deal. Institutional US investors .... well no institutional buying , no analyst report , Canacord shorted all their shares in the market from time Tolekis started talking to where they brought the price down. To add insult to injury Tolekis did not even look for another term sheet . Rumour has it another outfit said they would of done it at $2 with half warrant . Ask Tolekis if this true . If you don't believe me pm I LL give you the contact info of the firm .
Call the company and get what answers ? They will say the same things that you believe .